NGM NGM Biopharmaceuticals Inc.

14.9
-0.39  -3%
Previous Close 15.29
Open 15.29
Price To Book 2.84
Market Cap 984,040,193
Shares 66,042,966
Volume 128,746
Short Ratio
Av. Daily Volume 110,004

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1a/1b trial to be initiated 2H 2019.
NGM120
Cachexia syndrome
Phase 2 trial to be initiated 2020.
NGM313 / MK-3655
Non-alcoholic steatohepatitis (NASH) and Type 2 diabetes
Phase 1 trial initiated 2Q 2019.
NGM621
Geographic atrophy
Phase 2 interim cohort 4 data 4Q 2019.
NGM282
Non-alcoholic steatohepatitis (NASH)
Phase 2b initial data due by the end of 2020.
NGM282 - ALPINE 2/3
Non-alcoholic steatohepatitis (NASH)